Compare Pfizer Inc (PFE) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs S&P500 ETF — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while S&P500 ETF trades at $776.02 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 5.2× Pfizer Inc's market cap, and Pfizer Inc pays a 6.18% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and S&P500 ETF for 205 Days on average.
| PFE | SPY | |
|---|---|---|
Market Cap | $158.56B | $821.54B |
Volume | 44,138,282 | 40,070,358 |
Sector | Health | — |
52-Week High | $29.02 | $779.14 |
52-Week Low | $23.67 | $631.99 |
Typical Hold Time | 158 Days | 205 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF is near its pivot point of $776, with immediate resistance at $779. Recent news highlights mixed sentiment, with some articles pointing to strong corporate earnings growth in 2026 but expected deceleration in 2027, while others discuss defensive positioning and valuation concerns.
The outlook for SPY is cautiously optimistic, supported by bullish technical trends and robust earnings growth projections for 2026. Key risks include potential profit growth slowdown in 2027, elevated market valuations, and macroeconomic headwinds such as rising Treasury yields. Investors should weigh the ETF's broad market exposure against these factors for long-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
